Table 2. Clinical settings of durvalumab treatment.

Characteristics	No. respondents [%]
Multidisciplinary tumor board discussion about durvalumab after CRT
Yes	81 [57]
No	61 [43]
Unknown	1 [1]
PD-L1 status of patients present before CRT
In <10%	21 [15]
In 10–30%	30 [21]
In 31–50%	33 [23]
In >50%	57 [40]
No answer	2 [1]
amount of patients treated with durvalumab after CRT in stage III NSCLC
5–15	117 [82]
>15	20 [14]
Unknown	2 [1]
Specialist administering durvalumab after CRT
Medical oncologist (private practise)	46 [32]
Medical oncologist (general hospital)	40 [28]
Medical oncologist (university hospital)	41 [29]
Radiation oncologist who administered CRT	15 [11]
Unknown	1 [1]

CRT, chemoradiotherapy; PD-L1, programmed cell death ligand 1.